Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy.
carbon ions therapy
chordoma
proton therapy
skull base
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
29 09 2020
29 09 2020
Historique:
pubmed:
21
3
2020
medline:
28
4
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
The aim of this study is to evaluate results in terms of local control (LC), overall survival (OS), and toxicity profile and to better identify factors influencing clinical outcome of skull base chordoma treated with proton therapy (PT) and carbon ion radiotherapy (CIRT). We prospectively collected and analyzed data of 135 patients treated between November 2011 and December 2018. Total prescription dose in the PT group (70 patients) and CIRT group (65 patients) was 74 Gy relative biological effectiveness (RBE) delivered in 37 fractions and 70.4 Gy(RBE) delivered in 16 fractions, respectively (CIRT in unfavorable patients). LC and OS were evaluated using the Kaplan-Meier method. Univariate and multivariate analyses were performed, to identify prognostic factors on clinical outcomes. After a median follow-up of 44 (range, 6-87) months, 14 (21%) and 8 (11%) local failures were observed in CIRT and PT group, respectively. Five-year LC rate was 71% in CIRT cohort and 84% in PT cohort. The estimated 5-year OS rate in the CIRT and PT group was 82% and 83%, respectively. On multivariate analysis, gross tumor volume (GTV), optic pathways, and/or brainstem compression and dose coverage are independent prognostic factors of local failure risk. High rate toxicity grade ≥3 was reported in 11% of patients. Particle radiotherapy is an effective treatment for skull base chordoma with acceptable late toxicity. GTV, optic pathways, and/or brainstem compression and target coverage were independent prognostic factors for LC. • Proton and carbon ion therapy are effective and safe in skull base chordoma.• Prognostic factors are GTV, organs at risk compression, and dose coverage.• Dual particle therapy and customized strategy was adopted.
Sections du résumé
BACKGROUND
The aim of this study is to evaluate results in terms of local control (LC), overall survival (OS), and toxicity profile and to better identify factors influencing clinical outcome of skull base chordoma treated with proton therapy (PT) and carbon ion radiotherapy (CIRT).
METHODS
We prospectively collected and analyzed data of 135 patients treated between November 2011 and December 2018. Total prescription dose in the PT group (70 patients) and CIRT group (65 patients) was 74 Gy relative biological effectiveness (RBE) delivered in 37 fractions and 70.4 Gy(RBE) delivered in 16 fractions, respectively (CIRT in unfavorable patients). LC and OS were evaluated using the Kaplan-Meier method. Univariate and multivariate analyses were performed, to identify prognostic factors on clinical outcomes.
RESULTS
After a median follow-up of 44 (range, 6-87) months, 14 (21%) and 8 (11%) local failures were observed in CIRT and PT group, respectively. Five-year LC rate was 71% in CIRT cohort and 84% in PT cohort. The estimated 5-year OS rate in the CIRT and PT group was 82% and 83%, respectively. On multivariate analysis, gross tumor volume (GTV), optic pathways, and/or brainstem compression and dose coverage are independent prognostic factors of local failure risk. High rate toxicity grade ≥3 was reported in 11% of patients.
CONCLUSIONS
Particle radiotherapy is an effective treatment for skull base chordoma with acceptable late toxicity. GTV, optic pathways, and/or brainstem compression and target coverage were independent prognostic factors for LC.
KEY POINTS
• Proton and carbon ion therapy are effective and safe in skull base chordoma.• Prognostic factors are GTV, organs at risk compression, and dose coverage.• Dual particle therapy and customized strategy was adopted.
Identifiants
pubmed: 32193546
pii: 5810284
doi: 10.1093/neuonc/noaa067
pmc: PMC7523440
doi:
Substances chimiques
Protons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1348-1358Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Radiat Res. 2013 Jul;54 Suppl 1:i31-42
pubmed: 23824124
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1432-40
pubmed: 22349042
Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):59-68
pubmed: 9588918
Acta Oncol. 2005;44(7):700-8
pubmed: 16227160
Radiother Oncol. 2016 Jul;120(1):169-74
pubmed: 27247057
Clin Oncol (R Coll Radiol). 2011 Apr;23(3):199-208
pubmed: 20980136
Cancer. 2013 Jun 1;119(11):2029-37
pubmed: 23504991
Lancet Oncol. 2012 Feb;13(2):e69-76
pubmed: 22300861
Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):225-30
pubmed: 9226307
Radiother Oncol. 2019 Nov;140:175-181
pubmed: 31310888
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S36-41
pubmed: 20171516
J Comput Assist Tomogr. 2010 Jul;34(4):479-84
pubmed: 20657213
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1111-8
pubmed: 19386442
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):449-57
pubmed: 17363188
Radiother Oncol. 2019 Dec;141:227-233
pubmed: 31522881
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Neurosurg. 2007 Aug;107(2):319-24
pubmed: 17695386
Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):967-75
pubmed: 9392533
J Neurol Surg B Skull Base. 2014 Dec;75(6):383-90
pubmed: 25452895
Rep Pract Oncol Radiother. 2016 Jul-Aug;21(4):356-60
pubmed: 27330420
Lancet Oncol. 2015 Feb;16(2):e71-83
pubmed: 25638683
Radiother Oncol. 2016 Aug;120(2):307-12
pubmed: 27394694
Strahlenther Onkol. 1999 Jun;175 Suppl 2:57-63
pubmed: 10394399
Radiother Oncol. 2014 Apr;111(1):25-9
pubmed: 24332023
J Clin Neurosci. 2015 Nov;22(11):1792-6
pubmed: 26209919
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S28-35
pubmed: 20171514
Radiat Environ Biophys. 1997 Feb;36(1):59-66
pubmed: 9128899
Strahlenther Onkol. 2003 Apr;179(4):241-8
pubmed: 12707713
Neurosurgery. 2015 Feb;76(2):179-85; discussion 185-6
pubmed: 25594191
Skull Base. 2009 May;19(3):219-24
pubmed: 19881902
Med Phys. 2015 Sep;42(9):5287-300
pubmed: 26328978
J Neurosurg. 1999 Sep;91(3):432-9
pubmed: 10470818
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):304-311
pubmed: 26519991
Phys Med Biol. 2012 Nov 21;57(22):7543-54
pubmed: 23104051
Nat Rev Clin Oncol. 2010 Jan;7(1):37-43
pubmed: 19949433
Radiother Oncol. 2018 Aug;128(2):198-202
pubmed: 29310903
Cancer. 2014 Nov 1;120(21):3410-7
pubmed: 24948519
Neurosurgery. 2004 Dec;55(6):1252-60; discussion 1260-2
pubmed: 15574207
Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):201-10
pubmed: 10219815
Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):351-8
pubmed: 10487555
Phys Med Biol. 2000 Nov;45(11):3319-30
pubmed: 11098906
Radiat Oncol. 2019 Feb 1;14(1):24
pubmed: 30709366
World Neurosurg. 2018 Jan;109:307-327
pubmed: 29045855
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):396-401
pubmed: 16182466